2Q12 US Tysabri sales were $211M (+15% YoY, +5% QoQ), about 1/3 as much as US sales of Copaxone: http://www.biogenidec.com/PRESS_RELEASE_DETAILS.aspx?ID=5981&ReqId=1717583 Teva will report 2Q12 US sales of Copaxone on 8/2/12.